title: The impact of left ventricular size on response to cardiac resynchronization therapy.
abstract: Patients with nondilated (NDCM) or severely dilated cardiomyopathies (SDCM) have been underrepresented in clinical trials of cardiac resynchronization therapy (CRT). We examined changes in left ventricular ejection fraction (LVEF) and survival in patients with NDCM or SDCM compared with those with traditionally studied moderately dilated cardiomyopathy.
  
  
  METHODS
  We evaluated 800 consecutive patients undergoing the original implantation of a biventricular pacemaker between January 2004 and August 2007. For inclusion, patients had a baseline and pre-CRT echocardiogram, an LVEF ≤40%, a US social security number, and New York Heart Association class II to IV symptoms on standard medical therapy. Patients with a follow-up echocardiogram >2 months after device implantation were included in an analysis of remodeling. Using multivariate models, the impact of baseline left ventricular end-diastolic diameter (LVEDD) on change in LVEF and all-cause mortality was assessed.
  
  
  RESULTS
  A total of 668 patients met inclusion criteria and were included in the assessment of mortality. Four hundred seventy-one had an appropriately timed follow-up echocardiogram and were included in the analysis of remodeling. Patients in all 3 groups realized improvements in LVEF (%) after CRT as follows: NDCM (n = 137; LVEDD ≤5.5 cm) 10.0 ± 12.7, P < .001; moderately dilated cardiomyopathy (n = 233; LVEDD 5.6-6.9 cm) 8.2 ± 11.3, P < .001; and SDCM (n = 101; LVEDD ≥7.0 cm) 5.4 ± 9.4, P < .001. In multivariate analysis, baseline LVEDD was inversely associated with change in LVEF (parameter estimate -3.13 ± 0.56, P < .001) and directly associated with increased all-cause mortality (hazard ratio 1.25 [1.05-1.47] P = .01).
  
  
  CONCLUSIONS
  Patients with NDCM and SDCM experience significant improvements in LVEF after CRT. The degree of baseline left ventricular dilatation before CRT is an important predictor of subsequent changes in LVEF and survival.
authors: Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, OH, USA. rickarj2@ccf.org
authors: John
authors: J
authors: Rickard
authors: Danielle M
authors: DM
authors: Brennan
authors: David O
authors: DO
authors: Martin
authors: Eileen
authors: E
authors: Hsich
authors: W H Wilson
authors: WH
authors: Tang
authors: Bruce D
authors: BD
authors: Lindsay
authors: Randall C
authors: RC
authors: Starling
authors: Bruce L
authors: BL
authors: Wilkoff
authors: Richard A
authors: RA
authors: Grimm
mesh_terms: D000368:Aged; D058406:Cardiac Resynchronization Therapy; D002311:Cardiomyopathy, Dilated / Q000401:mortality / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D006352:Heart Ventricles / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D012189:Retrospective Studies; D013318:Stroke Volume; D015996:Survival Rate